14
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Comparative Pharmacological Evaluation of Different Sublingual Nitroglycerin Formulations

, , , &
Pages 193-209 | Published online: 20 Oct 2008
 

Abstract

Using a double blind, randomized cross-over design, the heart rate and systolic blood pressure of five healthy human subjects were compared following sublingual administration of three different nitroglycerin tablets and a placebo. The nitro-glycerin formulations included two commercially available tablets (one molded and one directly compressed) and an experimental tablet (directly compressed) which was developed in our laboratorq. Significant increase in heart.rate (P<0. 05) was demonstrated for two of the three nitroglycerin formulations when compared to placebo, but no difference in heart rate elevation could be observed among the three active products. Decrease in systolic blood pressure was shown to be a less consistt.nt circulatory response to sublingual nitroglycerin in this study, and no statistical significance (P > 0.05) in this parameter could be observed in the different treatments. It appeared that formulation factors such as addition of stabilizers and insoluble adjuvants to the dosage forms and change in tablet prt-paration methods did not significantly affect the pharmaculogical performance in circulatory effects of nitroglycerin.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.